跳至主要内容
临床试验/KCT0002640
KCT0002640
招募中
未知

A 12 week, randomized, double-blind, placebo-controlled clinical trial for the evaluation of the efficacy and safety of TabetriTM on atopic dermatitis in children

utri Biotech0 个研究点目标入组 60 人待定

概览

阶段
未知
干预措施
未指定
疾病 / 适应症
Diseases of the skin and subcutaneous tissue
发起方
utri Biotech
入组人数
60
状态
招募中
最后更新
7年前

概览

简要总结

暂无简介。

注册库
who.int
开始日期
待定
结束日期
待定
最后更新
7年前
研究类型
Interventional Study
性别
All

研究者

发起方
utri Biotech

入排标准

入选标准

  • 1\) Patients who agree to participate in this experiment and write consent including the subject and the parent (or legal representative)
  • 2\) Patients who aged 4\~12 years of both sexes
  • 3\) Patients who have had intermittent or persistent atopic dermatitis symptoms for more than 6 months
  • 4\) Patients with mide to moderate atopic dermatitis symptoms (SCORing of Atopic Dermatitis, SCORAD index range from 20 to 50\)

排除标准

  • 1\) Pateints who had severe skin disease, systemic disease
  • 2\) Patients who had prior treatments associated with atopic dermatitis, including systemic antibiotics, corticosteroids, anti\-histamines, immunosuppressant within 4 weeks prior to the study
  • 3\) Patients who administered medicine, herbal medicine, any health functional supplements to improve atopic dermatitis within 1 week
  • 4\) Patients who had phototherapy within 4 weeks prior to the study
  • 5\) Patients who plan to participate in another human body test during this experiment
  • 6\) Patients who participated in another human body test before this experiment within 4 weeks
  • 7\) Patients who is deemed by the examiner to be inappropriate for this experiment

结局指标

主要结局

未指定

相似试验